Cargando…
Usefulness of Functional Thyroid-Stimulating and Thyroid-Blocking Immunoglobulin Bioassays in an Atypical Presentation of Graves’ Disease
BACKGROUND/OBJECTIVE: Thyroid-stimulating hormone (TSH) receptor antibody (TRAb) is well recognized as the pathogenic antibody that causes the clinical manifestation of Graves’ disease (GD). Although the majority of TRAb measured in GD is due to thyroid-stimulating immunoglobulin (TSI), there are ot...
Autores principales: | Sherfan, Julie, Samad, Navira, Hsieh, Albert, Sullivan, David, Fuller, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association of Clinical Endocrinology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213846/ https://www.ncbi.nlm.nih.gov/pubmed/37251977 http://dx.doi.org/10.1016/j.aace.2023.02.004 |
Ejemplares similares
-
The Prediction Model Using Thyroid-stimulating Immunoglobulin Bioassay For Relapse of Graves’ Disease
por: Baek, Han-Sang, et al.
Publicado: (2022) -
The Early Changes in Thyroid-Stimulating Immunoglobulin Bioassay over Anti-Thyroid Drug Treatment Could Predict Prognosis of Graves’ Disease
por: Yu, Jin, et al.
Publicado: (2023) -
The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves’ disease
por: Zhou, Yulin, et al.
Publicado: (2021) -
Role of Maternal Thyroid-Stimulating Immunoglobulin in Graves' Disease for Predicting Perinatal Thyroid Dysfunction
por: Cui, Yiwen, et al.
Publicado: (2019) -
Elevated Graves’ Disease-Specific Thyroid-Stimulating Immunoglobulin and Thyroid Stimulating Hormone Receptor Antibody in a Patient With Subacute Thyroiditis
por: Alvin Mathew, Anu, et al.
Publicado: (2021)